What is Chardan Capital’s Forecast for SABS FY2025 Earnings?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Equities research analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for SAB Biotherapeutics in a research report issued to clients and investors on Monday, November 17th. Chardan Capital analyst K. Nakae now forecasts that the company will earn ($1.43) per share for the year, up from their prior estimate of ($1.97). Chardan Capital currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for SAB Biotherapeutics’ FY2026 earnings at ($1.12) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.38.

SABS has been the topic of a number of other research reports. Wall Street Zen raised shares of SAB Biotherapeutics to a “sell” rating in a report on Saturday, September 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SAB Biotherapeutics in a research note on Monday. Leerink Partners assumed coverage on shares of SAB Biotherapeutics in a research report on Wednesday, September 17th. They set an “outperform” rating and a $7.00 price objective for the company. Finally, Leerink Partnrs raised SAB Biotherapeutics to a “strong-buy” rating in a research report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, SAB Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $9.33.

SAB Biotherapeutics Trading Down 2.0%

SAB Biotherapeutics stock opened at $3.83 on Thursday. The business’s fifty day simple moving average is $2.69 and its two-hundred day simple moving average is $2.28. SAB Biotherapeutics has a 12 month low of $1.00 and a 12 month high of $6.60. The company has a current ratio of 10.49, a quick ratio of 0.87 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $39.87 million, a price-to-earnings ratio of -1.24 and a beta of 0.60.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of large investors have recently bought and sold shares of SABS. ADAR1 Capital Management LLC purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at $30,000. Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics during the third quarter valued at $32,000. Virtu Financial LLC purchased a new stake in SAB Biotherapeutics in the third quarter valued at $40,000. HB Wealth Management LLC grew its position in SAB Biotherapeutics by 10.9% during the 1st quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock worth $358,000 after purchasing an additional 25,800 shares during the period. Finally, Woodline Partners LP purchased a new position in shares of SAB Biotherapeutics during the 3rd quarter valued at about $5,730,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.